Nanobiotix (NBTX) Competitors

$52.04 +3.80 (+7.88%)

Closing price 04:00 PM Eastern

Extended Trading

$52.04 +0.01 (+0.01%)

As of 04:26 PM Eastern

NBTX vs. MIRM, PTGX, RYTM, COGT, and BLTE

Should you buy Nanobiotix stock or one of its competitors? MarketBeat compares Nanobiotix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nanobiotix include Mirum Pharmaceuticals (MIRM), Protagonist Therapeutics (PTGX), Rhythm Pharmaceuticals (RYTM), Cogent Biosciences (COGT), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical products" industry.

How does Nanobiotix compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Nanobiotix (NASDAQ:NBTX) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

Mirum Pharmaceuticals has higher revenue and earnings than Nanobiotix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	12.77	-$23.36M	-$13.61	N/A
Nanobiotix	$36.87M	68.48	-$27.11M	N/A	N/A

Mirum Pharmaceuticals currently has a consensus price target of $136.42, suggesting a potential upside of 24.97%. Nanobiotix has a consensus price target of $26.67, suggesting a potential downside of 48.76%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Mirum Pharmaceuticals is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Mirum Pharmaceuticals has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market.

38.8% of Nanobiotix shares are owned by institutional investors. 14.4% of Mirum Pharmaceuticals shares are owned by insiders. Comparatively, 3.5% of Nanobiotix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Mirum Pharmaceuticals had 22 more articles in the media than Nanobiotix. MarketBeat recorded 26 mentions for Mirum Pharmaceuticals and 4 mentions for Nanobiotix. Mirum Pharmaceuticals' average media sentiment score of 0.36 beat Nanobiotix's score of 0.18 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	6 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Nanobiotix	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nanobiotix has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Nanobiotix's return on equity of 0.00% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Nanobiotix	N/A	N/A	N/A

Summary

Mirum Pharmaceuticals beats Nanobiotix on 9 of the 15 factors compared between the two stocks.

How does Nanobiotix compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Nanobiotix (NASDAQ:NBTX) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Nanobiotix has a net margin of 0.00% compared to Protagonist Therapeutics' net margin of -154.88%. Nanobiotix's return on equity of 0.00% beat Protagonist Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Nanobiotix	N/A	N/A	N/A

Nanobiotix has lower revenue, but higher earnings than Protagonist Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	145.17	-$130.15M	-$1.81	N/A
Nanobiotix	$36.87M	68.48	-$27.11M	N/A	N/A

Protagonist Therapeutics has a beta of 1.89, indicating that its stock price is 89% more volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market.

Protagonist Therapeutics currently has a consensus target price of $113.69, suggesting a potential upside of 9.45%. Nanobiotix has a consensus target price of $26.67, suggesting a potential downside of 48.76%. Given Protagonist Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Protagonist Therapeutics is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Protagonist Therapeutics had 12 more articles in the media than Nanobiotix. MarketBeat recorded 16 mentions for Protagonist Therapeutics and 4 mentions for Nanobiotix. Protagonist Therapeutics' average media sentiment score of 0.19 beat Nanobiotix's score of 0.18 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nanobiotix	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 38.8% of Nanobiotix shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by insiders. Comparatively, 3.5% of Nanobiotix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Protagonist Therapeutics beats Nanobiotix on 10 of the 14 factors compared between the two stocks.

How does Nanobiotix compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Nanobiotix (NASDAQ:NBTX) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

Nanobiotix has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -93.33%. Nanobiotix's return on equity of 0.00% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
Nanobiotix	N/A	N/A	N/A

Nanobiotix has lower revenue, but higher earnings than Rhythm Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	33.85	-$196.54M	-$3.13	N/A
Nanobiotix	$36.87M	68.48	-$27.11M	N/A	N/A

Rhythm Pharmaceuticals has a beta of 1.94, indicating that its share price is 94% more volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market.

Rhythm Pharmaceuticals currently has a consensus target price of $131.81, suggesting a potential upside of 40.65%. Nanobiotix has a consensus target price of $26.67, suggesting a potential downside of 48.76%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Rhythm Pharmaceuticals is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.84
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Rhythm Pharmaceuticals had 15 more articles in the media than Nanobiotix. MarketBeat recorded 19 mentions for Rhythm Pharmaceuticals and 4 mentions for Nanobiotix. Rhythm Pharmaceuticals' average media sentiment score of 0.38 beat Nanobiotix's score of 0.18 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nanobiotix	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

38.8% of Nanobiotix shares are held by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are held by company insiders. Comparatively, 3.5% of Nanobiotix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Rhythm Pharmaceuticals beats Nanobiotix on 9 of the 15 factors compared between the two stocks.

How does Nanobiotix compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Nanobiotix (NASDAQ:NBTX) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Cogent Biosciences has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market.

Nanobiotix's return on equity of 0.00% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Nanobiotix	N/A	N/A	N/A

38.8% of Nanobiotix shares are held by institutional investors. 7.3% of Cogent Biosciences shares are held by company insiders. Comparatively, 3.5% of Nanobiotix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Nanobiotix has higher revenue and earnings than Cogent Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Nanobiotix	$36.87M	68.48	-$27.11M	N/A	N/A

Cogent Biosciences presently has a consensus price target of $43.73, suggesting a potential upside of 27.52%. Nanobiotix has a consensus price target of $26.67, suggesting a potential downside of 48.76%. Given Cogent Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Cogent Biosciences is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Cogent Biosciences had 3 more articles in the media than Nanobiotix. MarketBeat recorded 7 mentions for Cogent Biosciences and 4 mentions for Nanobiotix. Cogent Biosciences' average media sentiment score of 0.98 beat Nanobiotix's score of 0.18 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Nanobiotix	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Cogent Biosciences beats Nanobiotix on 7 of the 13 factors compared between the two stocks.

How does Nanobiotix compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Nanobiotix (NASDAQ:NBTX) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Nanobiotix's return on equity of 0.00% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-19.49%	-19.05%
Nanobiotix	N/A	N/A	N/A

Belite Bio has a beta of -1.19, suggesting that its stock price is 219% less volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market.

0.5% of Belite Bio shares are held by institutional investors. Comparatively, 38.8% of Nanobiotix shares are held by institutional investors. 13.3% of Belite Bio shares are held by company insiders. Comparatively, 3.5% of Nanobiotix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Belite Bio had 6 more articles in the media than Nanobiotix. MarketBeat recorded 10 mentions for Belite Bio and 4 mentions for Nanobiotix. Belite Bio's average media sentiment score of 0.71 beat Nanobiotix's score of 0.18 indicating that Belite Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nanobiotix	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Belite Bio presently has a consensus price target of $202.33, suggesting a potential upside of 31.80%. Nanobiotix has a consensus price target of $26.67, suggesting a potential downside of 48.76%. Given Belite Bio's stronger consensus rating and higher probable upside, analysts clearly believe Belite Bio is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Nanobiotix has higher revenue and earnings than Belite Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.30	N/A
Nanobiotix	$36.87M	68.48	-$27.11M	N/A	N/A

Summary

Belite Bio and Nanobiotix tied by winning 6 of the 12 factors compared between the two stocks.

Get Nanobiotix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NBTX vs. The Competition

Export

Metric	Nanobiotix	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.34B	$3.04B	$6.31B	$12.20B
Dividend Yield	N/A	1.97%	2.79%	5.30%
P/E Ratio	N/A	18.86	21.23	25.65
Price / Sales	68.48	289.31	558.10	79.79
Price / Cash	N/A	56.53	42.94	55.34
Price / Book	-26.42	4.35	9.70	6.66
Net Income	-$27.11M	$72.19M	$3.55B	$333.63M
7 Day Performance	24.32%	-2.82%	-1.10%	-0.79%
1 Month Performance	62.63%	1.37%	2.57%	5.33%
1 Year Performance	1,284.04%	46.50%	40.47%	36.26%

Nanobiotix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NBTX Nanobiotix	1.3815 of 5 stars	$52.04 +7.9%	$26.67 -48.8%	+1,348.6%	$2.34B	$36.87M	N/A	100	Short Interest Increase Gap Up
MIRM Mirum Pharmaceuticals	2.5774 of 5 stars	$107.18 +1.3%	$125.25 +16.9%	+134.5%	$6.54B	$521.31M	N/A	140	Earnings Report Analyst Revision
PTGX Protagonist Therapeutics	1.8107 of 5 stars	$98.64 -0.9%	$108.15 +9.6%	+120.8%	$6.34B	$46.02M	N/A	120	Positive News Insider Trade
RYTM Rhythm Pharmaceuticals	2.4076 of 5 stars	$91.49 +6.9%	$131.13 +43.3%	+54.8%	$6.27B	$189.76M	N/A	140	Trending News Analyst Revision Gap Up
COGT Cogent Biosciences	3.3027 of 5 stars	$36.38 -1.0%	$43.45 +19.4%	+573.1%	$6.21B	N/A	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NBTX) was last updated on 5/13/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nanobiotix (NBTX) Competitors

NBTX vs. MIRM, PTGX, RYTM, COGT, and BLTE

How does Nanobiotix compare to Mirum Pharmaceuticals?

Summary

How does Nanobiotix compare to Protagonist Therapeutics?

Summary

How does Nanobiotix compare to Rhythm Pharmaceuticals?

Summary

How does Nanobiotix compare to Cogent Biosciences?

Summary

How does Nanobiotix compare to Belite Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBTX vs. The Competition

Nanobiotix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nanobiotix (NBTX) Competitors

NBTX vs. MIRM, PTGX, RYTM, COGT, and BLTE

How does Nanobiotix compare to Mirum Pharmaceuticals?

Which has better earnings and valuation, MIRM or NBTX?

Do analysts prefer MIRM or NBTX?

Which has more volatility & risk, MIRM or NBTX?

Do insiders and institutionals have more ownership in MIRM or NBTX?

Does the media prefer MIRM or NBTX?

Is MIRM or NBTX more profitable?

Summary

How does Nanobiotix compare to Protagonist Therapeutics?

Is PTGX or NBTX more profitable?

Which has better valuation & earnings, PTGX or NBTX?

Which has more risk & volatility, PTGX or NBTX?

Do analysts recommend PTGX or NBTX?

Does the media refer more to PTGX or NBTX?

Do insiders & institutionals have more ownership in PTGX or NBTX?

Summary

How does Nanobiotix compare to Rhythm Pharmaceuticals?

Is RYTM or NBTX more profitable?

Which has preferable earnings & valuation, RYTM or NBTX?

Which has more volatility and risk, RYTM or NBTX?

Do analysts recommend RYTM or NBTX?

Does the media prefer RYTM or NBTX?

Do institutionals & insiders have more ownership in RYTM or NBTX?

Summary

How does Nanobiotix compare to Cogent Biosciences?

Which has more risk and volatility, COGT or NBTX?

Is COGT or NBTX more profitable?

Do insiders and institutionals have more ownership in COGT or NBTX?

Which has better earnings and valuation, COGT or NBTX?

Do analysts recommend COGT or NBTX?

Does the media prefer COGT or NBTX?

Summary

How does Nanobiotix compare to Belite Bio?

Is BLTE or NBTX more profitable?

Which has more risk and volatility, BLTE or NBTX?

Do insiders and institutionals have more ownership in BLTE or NBTX?

Does the media prefer BLTE or NBTX?

Do analysts recommend BLTE or NBTX?

Which has better earnings and valuation, BLTE or NBTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBTX vs. The Competition

Nanobiotix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools